In prostate cancer, FOXO mutations are rare (<0.5% incidence), however FOXO1 and FOXO3 deep deletion is a frequent event, occurring in up to 15.2% and 13.4% of patients respectively (Tables S1–S3). This evidence concerns the gene FOXO3 and Familial prostate cancer.